Research Topics
| Thomas MonathSummaryAffiliation: Acambis Inc Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacyJuan Arroyo
Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
J Virol 78:12497-507. 2004..The safety, immunogenicity, and efficacy of the ChimeriVax-WN(02) vaccine in the macaque model indicate the vaccine candidate is expected to be safe and immunogenic for humans...- Recombination and flavivirus vaccines: a commentaryThomas P Monath
Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
Vaccine 23:2956-8. 2005 - Prospects for development of a vaccine against the West Nile virusT P Monath
Research and Medical Affairs, Acambis Incorporated, Cambridge, Massachusetts 02139, USA
Ann N Y Acad Sci 951:1-12. 2001..The chimeric virus replicates in the host like yellow fever 17D but immunizes specifically against West Nile virus... - Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeysThomas P Monath
Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
Biologicals 33:131-44. 2005..The test in infant mice is particularly useful as a means of demonstrating biological consistency across seed virus and vaccine lots... - ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defenseThomas P Monath
Acambis Inc, 38, Sidney Street, Cambridge, MA 02139, USA
Int J Infect Dis 8:S31-44. 2004..The vaccines produced major cutaneous reactions and evoked neutralizing antibody and cell-mediated immune responses in the vast majority of subjects and had a reactogenicity profile similar to that of Dryvax... - West Nile virus vaccineT P Monath
Acambis Inc, 38 Sidney Street, Cambridge, Massachusetts 02139, USA
Curr Drug Targets Infect Disord 1:37-50. 2001.... - Yellow fever vaccineThomas P Monath
Acambis, Inc, 38 Sidney Street, MA 02139, USA
Expert Rev Vaccines 4:553-74. 2005.... - Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigenThomas P Monath
Acambis Inc, Cambridge, Massachusetts, USA
J Infect Dis 188:1213-30. 2003..Anamnestic responses were observed in preimmune individuals. ChimeriVax-JE appears to be a safe vaccine that provides protective levels of neutralizing antibody after a single dose... - A live, attenuated recombinant West Nile virus vaccineThomas P Monath
Acambis, 38 Sidney Street, Cambridge, MA 02139, USA
Proc Natl Acad Sci U S A 103:6694-9. 2006..ChimeriVax-WN02 rapidly elicits strong immune responses after a single dose, and is a promising candidate warranting further evaluation for prevention of WN disease... - Yellow fever 17D vaccine safety and immunogenicity in the elderlyThomas P Monath
Acambis, Cambridge, Massachusetts 02139, USA
Hum Vaccin 1:207-14. 2005..The neutralizing antibody response, which is the mediator of protective immunity to YF, is not diminished in healthy, elderly persons... - Prevention of yellow fever in persons traveling to the tropicsThomas P Monath
Research and Medical Affairs, Acambis, Cambridge, MA 02139, USA
Clin Infect Dis 34:1369-78. 2002..To avoid unnecessary vaccination, physicians should vaccinate persons at risk on the basis of knowledge of the epidemiology of the disease, reports of epidemic activity, season, and the likelihood of exposure to vector mosquitoes... - Yellow fever as an endemic/epidemic disease and priorities for vaccinationT P Monath
Acambis, 38 Sidney Street, Cambridge MA 01451, USA
Bull Soc Pathol Exot 99:341-7. 2006..However, vaccine policy in non-endemic coastal regions of South America must weigh the risk of vaccine-related adverse events against the theoretical benefit of preventing urban yellow fever... - Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccinesThomas P Monath
Acambis Inc, Cambridge, Massachusetts 02139, USA
J Virol 76:1932-43. 2002..These results are consistent with the observation that empirically derived vaccines developed by mouse brain passage of dengue and YF viruses have increased neurovirulence for mice but reduced viscerotropism for humans... - A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirusCaroline C Maier
Virology Department, Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
Virology 362:468-74. 2007..A possible interpretation of these observations is that M can modulate the envelope (E) protein function during cell infection... - Traditional and novel approaches to flavivirus vaccinesKonstantin V Pugachev
Acambis, Inc, 38 Sidney Street, Cambridge, MA 02139, USA
Int J Parasitol 33:567-82. 2003..Other approaches, such as the construction of protein subunit, expression vector-based and naked DNA vaccines, have been proposed to create alternate vaccine candidates... - High fidelity of yellow fever virus RNA polymeraseKonstantin V Pugachev
Acambis, Inc, Cambridge, Massachusetts 02139, USA
J Virol 78:1032-8. 2004.... - Clonal vaccinia virus grown in cell culture as a new smallpox vaccineRichard Weltzin
Acambis Inc, 38 Sidney Street, Cambridge, Massachusetts 02139, USA
Nat Med 9:1125-30. 2003..The vaccines were equivalent in their ability to produce major cutaneous reactions ('takes') and to induce neutralizing antibody and cell-mediated immunity against vaccinia virus... - New developments in flavivirus vaccines with special attention to yellow feverKonstantin V Pugachev
Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
Curr Opin Infect Dis 18:387-94. 2005..To further reduce the impact of flavivirus diseases, vaccination policies and vector control programs in affected countries require revision... - Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypesFarshad Guirakhoo
Acambis, Inc, Cambridge, Massachusetts 02139, USA
Hum Vaccin 2:60-7. 2006..The latter observation can have practical implications toward development of a dengue vaccine... - Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic toolKonstantin V Pugachev
Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
Am J Trop Med Hyg 71:639-45. 2004..These chimeras have the potential for use as diagnostic reagents and vaccines against SLE and WN... - Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimenPatricia Londoño-Arcila
Acambis Ltd, Cambridge, United Kingdom
Infect Immun 70:5096-106. 2002..The significance of these findings with regard to development of a human vaccine against H. pylori and modulation of immune responses by heterologous prime-boost immunization regimens is discussed... - Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infectionsThomas P Monath
Research and Medical Affairs, Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
Vaccine 20:1004-18. 2002..The new vaccine holds promise for prevention of JE in travelers and residents of endemic countries. The ChimeriVax technology platform is being exploited for development of new vaccines against dengue and West Nile... - Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE)Konstantin V Pugachev
Acambis, Inc, 38 Sidney St, Cambridge, MA 02139, USA
Vaccine 25:6661-71. 2007..These data provide strong experimental evidence that the potential of recombinants, should they ever emerge, to cause disease or spread (compete in nature with wild-type flaviviruses) would be indeed extremely low... - Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trialThomas P Monath
Acambis, Cambridge Massachusetts 02139, USA
Am J Trop Med Hyg 66:533-41. 2002..Adverse events were less frequent in individuals with preexisting immunity to YF, indicating a relationship to virus replication... - Pathogenesis and pathophysiology of yellow feverThomas P Monath
Acambis Inc. and Department of Microbiology and Immunology, Harvard School of Public Health, Cambridge, Massachusetts 02139, USA
Adv Virus Res 60:343-95. 2003.... - Possible autoimmune reactions following smallpox vaccination: the biologic false positive test for syphilisThomas P Monath
Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, United States
Vaccine 27:1645-50. 2009..One subject with myocarditis was RPR-negative. One RPR-positive and 1 RPR-negative subject had elevated CK-MB enzymes without other evidence for myocarditis... - Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencingKonstantin V Pugachev
Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
Vaccine 20:996-9. 2002..e. did not result in an amino acid change). The differences are inconsequential to safety and effectiveness of ARILVAX. Other YF 17D vaccines are undoubtedly also heterogeneous and need to be re-examined using the consensus approach... - Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin ASamer Aboudola
Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Infect Immun 71:1608-10. 2003..These findings support the feasibility of using a vaccine to protect high-risk individuals against C. difficile-associated diarrhea and colitis... - Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrheaStavros Sougioultzis
Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, 02215, USA
Gastroenterology 128:764-70. 2005..The results of this study support the feasibility of active vaccination against C difficile and its toxins in high-risk individuals but must be validated in larger, randomized, controlled trials... - 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005Alan D T Barrett
Sealy Centre for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555 0609, USA
Vaccine 25:2758-65. 2007.... - Viral vectors for malaria vaccine developmentShengqiang Li
PATH Malaria Vaccine Initiative, Bethesda, MD, USA
Vaccine 25:2567-74. 2007..Understanding the vector's ability to induce an immune response and the expression of malaria antigens in mammalian cells will be critical in designing the next generation of viral-vectored malaria vaccines... - Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primatesCheryl H Dean
BD Technologies, Research Triangle Park, North Carlina, USA
Hum Vaccin 1:106-11. 2005..Thus, cutaneous delivery may represent a minimally-invasive alternative approach for flavivirus vaccines that more closely resembles the natural route of viral infection... - Editorial: jennerian vaccination against West Nile virusThomas P Monath
Am J Trop Med Hyg 66:113-4. 2002 - Lack of transmission of vaccinia virusJames H Stark
Emerg Infect Dis 12:698-700. 2006 - Yellow fever: 100 years of discoveryJ Erin Staples
Arboviral Diseases Branch, Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention, 3150 Rampart Rd, Fort Collins, CO 80521, USA
JAMA 300:960-2. 2008 - Safety of flavivirus chimeric vaccines: answer to Ishikawa et al. [Vaccine 26 (22) (2008) 2772-2781]Bruno Guy
Vaccine 26:4107-8. 2008 - Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE)Mark Reid
Australian Army Malaria Institute, Brisbane, Queensland, Australia
Am J Trop Med Hyg 75:659-63. 2006..vigilax was infected when fed on YF 17D. The results suggest that none of these three species of mosquito are likely to set up secondary cycles of transmission of ChimeriVax-JE in Australia after feeding on a viremic vaccinee... - Exercise-induced serum enzyme elevations confounding the evaluation of investigational drug toxicity. Report of two cases in a vaccine trialCasey Johnson
Pharmaceutical Research Associates Inc, Lenexa, Kansas, USA
Hum Vaccin 1:24-9. 2005..The inclusion of placebo control arm (in lieu of or addition to an active vaccine control) will also be useful in differentiating causally related serum enzyme elevations... - Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challengeKathleen A Marriott
Battelle Biomedical Research Center, West Jefferson, OH 43162, USA
Vaccine 26:581-8. 2008..The protective efficacy of ACAM2000 was found to be equivalent to the currently approved vaccine, Dryvax... - Dengue and yellow fever--challenges for the development and use of vaccinesThomas P Monath
Kleiner Perkins Caulfield and Byers, Menlo Park, CA, USA
N Engl J Med 357:2222-5. 2007 - Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from ThailandStephen Higgs
Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555 0609, USA
Am J Trop Med Hyg 75:986-93. 2006..Considering the low level viremias anticipated in humans vaccinated with these viruses, it is predicted that the risks of infection and transmission by mosquitoes in nature is minimal... - Host-range restriction of chimeric yellow fever-West Nile vaccine in fish crows (Corvus ossifragus)Stanley A Langevin
Centers for Disease Control and Prevention, Fort Collins, Colorado 80522, USA
Am J Trop Med Hyg 69:78-80. 2003..However, if used in mammals, this recombinant viral vaccine is unlikely to inadvertently enter a natural transmission cycle with birds as amplifying hosts... - High rates of recurrence and of transient reinfections of Helicobacter pylori in a population with high prevalence of infectionYelda Leal-Herrera
, , Instituto Mexicano del Seguro Social, ,
Am J Gastroenterol 98:2395-402. 2003..In several cases, reinfection occurred by multiple strains, which suggests that soon after eradication, patients are exposed to multiple sources of reinfection... - Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitisCHING JUH LAI
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Adv Virus Res 61:469-509. 2003..The chimeric flavivirus strategy has led to the rapid development of novel live-attenuated vaccines against dengue, TBE, JE, and West Nile viruses... - Epidemiology and ecology of yellow fever virusAlan D Barrett
Center for Biodefense and Emerging Infectious Diseases, Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, Texas 77555-0609, USA
Adv Virus Res 61:291-315. 2003 - Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reactionBarbara W Johnson
Division of Vector Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado 80521, USA
Am J Trop Med Hyg 70:89-97. 2004..Therefore, it is unlikely that a mosquito feeding on a viremic vaccinee, would become infected with the chimeric viruses. Thus, there is very little potential for transmission by mosquitoes of the ChimeriVax-DEN vaccine viruses... - Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccineDavid W C Beasley
Department of Pathology, Sealy Center for Vaccine Development, and Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555 0609, USA
Vaccine 22:3722-6. 2004..ChimeriVax-JE stimulated protection that was comparable or superior to the JE-VAX control... - Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster modelRobert B Tesh
University of Texas Medical Branch, Galveston 77555, USA
Emerg Infect Dis 8:1392-7. 2002.... - Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pyloriStavros Sougioultzis
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Vaccine 21:194-201. 2002..In conclusion, rectal delivery of 5 microg LT is safe and induces vigorous systemic anti-LT immune responses. Further studies are needed to determine if LT can be an effective adjuvant for rectally delivered antigens... - Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in PeruVivian E Belmusto-Worn
U S Naval Medical Research Center Detachment, Lima, Peru
Am J Trop Med Hyg 72:189-97. 2005..There were no treatment-related serious AEs. This is the first randomized, double-blind comparison of two YF vaccines in a pediatric population; both vaccines were shown to be highly immunogenic and well-tolerated... - Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002Martin S Cetron
Division of Global Migration and Quarantine, National Center for Infectious Diseases, CDC, USA
MMWR Recomm Rep 51:1-11; quiz CE1-4. 2002..cdc.gov/travel/index.htm, and through the website for the Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, CDC, at http://www.cdc.gov/ncidod/ dvbid/yellowfever/index.htm... - Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoesBarbara W Johnson
Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado 80522, USA
Am J Trop Med Hyg 67:260-5. 2002..Therefore, transmission of ChimeriVax-DEN2 virus by vector mosquitoes is unlikely... - A novel, cell culture-derived smallpox vaccine in vaccinia-naive adultsAndrew W Artenstein
Center for Biodefense and Emerging Pathogens, Division of Infectious Diseases, Memorial Hospital of Rhode Island, Pawtucket, USA
Vaccine 23:3301-9. 2005..One subject who received ACAM2000 developed myopericarditis. In healthy, primary vaccines ACAM2000 has a similar vaccination success rate, antibody response, and safety profile to Dryvax... - Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cellsSamantha Brandler
Institute of Virology, Medical University of Vienna, Vienna, Austria
Am J Trop Med Hyg 72:74-81. 2005..The lack of growth of chimeric viruses in human hepatic cells suggests that these viruses may be less hepatotropic than YF 17D virus vaccine in humans... - Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapyGiselle Soto
Asociacion Benefica PRISMA, Lima, Peru
J Infect Dis 188:1263-75. 2003..Although eradication with antibiotics was successful, the high rate of reinfection suggests that treatment is unlikely to have a lasting public health effect in this setting... - Treatment of yellow feverThomas P Monath
Kleiner Perkins Caufield and Byers, Menlo Park, CA, United States
Antiviral Res 78:116-24. 2008.... - Preface to volume 60 the flaviviruses: pathogenesis and immunityThomas J Chambers
Adv Virus Res 60:xiii-xiv. 2003 - Preface to the flavivirusesThomas J Chambers
Adv Virus Res 60:ix-xi. 2003 - Specific immunoglobulin A antibodies in maternal milk and delayed Helicobacter pylori colonization in Gambian infantsJulian E Thomas
Medical Research Council Human Nutrition Research, Keneba, The Gambia
Clin Infect Dis 39:1155-60. 2004..Immunoglobulin A (IgA) in maternal milk may protect Gambian infants from early Helicobacter pylori colonization. This study sought evidence that this protection could be due to specific IgA antibodies... - Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functionsGetahun Abate
Department of Internal Medicine, Saint Louis University, St. Louis, Missouri 63110, USA
J Infect Dis 192:1362-71. 2005..CFSE-based flow-cytometric assays will be useful in evaluating cell-mediated immune responses induced by new smallpox vaccines...
Research Grants
- LIVE, ATTENUATED, RECOMBINANT VACCINE - WEST NILE VIRUSThomas Monath; Fiscal Year: 2002..abstract_text> ..